News Passage Bio, Inc.

Equities

PASG

US7027121000

Delayed Nasdaq Other stock markets 02:33:47 2024-06-05 pm EDT			5-day change	1st Jan Change
1.265 ^USD	+2.02%		+6.30%	+25.25%

May. 15	Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating	MT
May. 14	Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference	07:30am	GL
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award	May. 21	AQ
Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating	May. 15	MT
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights	May. 14	GL
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights	May. 14	AQ
PASSAGE BIO TO PRESENT AT CHARDAN'S 8TH ANNUAL GENETIC MEDICINES AND CELL THERAPY MANUFACTURING SUMMIT	Apr. 23	AQ
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit	Apr. 22	GL
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program	Mar. 05	AQ
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer	Mar. 04	CI
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights	Mar. 04	GL
Passage Bio to Participate in Upcoming Investor Conferences	Feb. 27	GL
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Jan. 31	GL
Passage Bio : IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE - Form 8-K	Dec. 29	PU
Passage Bio Says Data From Phase 1/2 Trial of Dementia Therapy Exceeded Expectations	Dec. 20	MT
Transcript : Passage Bio, Inc. - Special Call	Dec. 20
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities	Dec. 20	GL
Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities	Dec. 20	CI
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)	Nov. 17	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Passage Bio, Inc.

Equities

PASG

US7027121000

Summary

Filters